Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06909565 · ClinicalTrials.gov registry record · Phase 4
Inclisiran Versus Placebo for the Prevention of Major Adverse Cardiovascular and Limb Events in Patients Undergoing Percutaneous Coronary Intervention or Peripheral Endovascular Intervention
A Phase 4 study of Percutaneous Coronary Intervention and Peripheral Endovascular Intervention, sponsored by Duke University.
- Recruiting
- Registry status
- Phase 4
- Development phase
- 6,000
- Enrollment target
- 20
- Study locations
NCT06909565 is a Phase 4 study of Percutaneous Coronary Intervention and Peripheral Endovascular Intervention that is actively recruiting participants, run by Duke University. The registered enrollment target is 6,000 participants, above the 4,725-participant average among 12 other Percutaneous Coronary Intervention trials with a reported enrollment target (27% higher). The trial reports 20 study locations across 5 states.
The verdict
NCT06909565, a Phase 4 study of Percutaneous Coronary Intervention and Peripheral Endovascular Intervention, is actively recruiting participants, sponsored by Duke University.
- RECRUITING
- Registry status
- Phase 4
- Development phase
- 6,000 participants
- Enrollment target
- 20
- Study locations
Study Summary
V-INTERVENTION will evaluate the effectiveness of inclisiran in preventing major cardiovascular and limb events in patients receiving percutaneous coronary or peripheral arterial revascularization. Inclisiran is a subcutaneous, twice-yearly injection that is FDA-approved as an adjunct with statin therapy and on the market to lower LDL-C in high-risk populations.
Conditions Studied
Interventions
- DRUG Inclisiran sodium 300 mg (equivalent to 284 mg inclisiran) in 1.5 mL
- DRUG Normal Saline (Placebo)
Study Locations (20)
Florida
- BayCare Medical Group - Clearwater
- Clearwater Cardiovascular Consultants - Clearwater
- Pioneer Clinical Studies - Coral Gables
- Arrow Clinical Trails - Daytona Beach
- Clearwater Cardiovascular and Interventional Consultants- Bardmoor - Largo
- Inpatient Research Clinic, LLC - Miami Lakes
- Cardiovascular Institute of Northwest Florida - Panama City
- Charlotte Heart & Vascular Center, PA - Port Charlotte
- Clearwater Cardiovascular Consultants - Safety Harbor
California
- Pacific Oaks Medical Group - Beverly Hills
- Valley Clinical Trials - Covina
- Radin Cardiovascular Medical Group, Inc - Newport Beach
- Valley Clinical Trials, LLC - Flourish Research - Northridge
- Riverside Community Hospital - Riverside
- The Heart Medical Group - Van Nuys
- Interventional Cardiology Medical Group - West Hills
Alabama
- Advanced Cardiovascular LLC - Alexander City
- Heart Center Research, LLC - Huntsville
Arkansas
- Arkansas Cardiology - Little Rock
Connecticut
- Cardiology Associates of Fairfield County - Stamford
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 6,000 participants |
| Start Date | 2025-07-23 |
| Est. Completion | 2029-12 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06909565
The ClinicalTrials.gov registry entry for NCT06909565 describes a study currently listed as recruiting, categorized as Phase 4. The registered enrollment target is 6,000 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 4,725-participant average among 12 other Percutaneous Coronary Intervention trials with a reported enrollment target (27% higher). The listed sponsor is Duke University, which has 1,725 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Percutaneous Coronary Intervention appearing as the primary indexed condition, and to 2 interventions - of which Inclisiran sodium 300 mg (equivalent to 284 mg inclisiran) in 1.5 mL is the first listed.
NCT06909565 reports 20 study locations spanning 5 distinct geographic areas - top geographies include Florida, California, Alabama.
Frequently Asked Questions
What is clinical trial NCT06909565 about?
NCT06909565 is a clinical study titled "Inclisiran Versus Placebo for the Prevention of Major Adverse Cardiovascular and Limb Events in Patients Undergoing Percutaneous Coronary Intervention or Peripheral Endovascular Intervention". V-INTERVENTION will evaluate the effectiveness of inclisiran in preventing major cardiovascular and limb events in patients receiving percutaneous coronary or peripheral arterial revascularization. Inclisiran is a subcutaneous, twice-yearly injection that is FDA-approved as an adjunct with statin th...
What is the current status of trial NCT06909565?
This trial is currently recruiting. It is a Phase 4 study. The enrollment target is 6,000 participants. The study started on 2025-07-23. Estimated completion is 2029-12.
What conditions does trial NCT06909565 study?
This clinical trial studies the following conditions: Percutaneous Coronary Intervention, Peripheral Endovascular Intervention.
What interventions are being tested in trial NCT06909565?
The interventions under investigation include: Inclisiran sodium 300 mg (equivalent to 284 mg inclisiran) in 1.5 mL (DRUG), Normal Saline (Placebo) (DRUG).
Who is sponsoring clinical trial NCT06909565?
This trial is sponsored by Duke University, which has 1,725 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06909565 being conducted?
This trial has 20 study locations across Alabama, Arkansas, California, Connecticut, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Percutaneous Coronary Intervention
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Chewed Versus Integral Pill of Ticagrelor
COMPLETED · Phase 4
-
Improving Cardiac Rehabilitation Exercise Using Target Heart Rate Trial
RECRUITING · Phase 2
-
Remote Ischemic Preconditioning for Renal and Cardiac Protection in Congestive Heart Failure (RICH) Trial
RECRUITING · Phase 2
-
Advancing Cath Lab Results With FFRangio Coronary Physiology Assessment
ACTIVE NOT RECRUITING · NA
-
Native Coronary Artery Instead of SAphenous Vein Graft Intervention for Treatment of Significant Saphenous Vein Graft Lesions
ACTIVE NOT RECRUITING
-
Precision PCI Registry
ACTIVE NOT RECRUITING
Explore more on PlainTrial
Percutaneous Coronary Intervention
All registered trials for this condition
Peripheral Endovascular Intervention
All registered trials for this condition
Alabama
All trials with a study site in Alabama
Recruiting now
Find trials open to new participants near you
Rankings
Top sponsors, conditions, and phases
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.